These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 27938492)

  • 1. Histone Acetyltransferase 1 Promotes Cell Proliferation and Induces Cisplatin Resistance in Hepatocellular Carcinoma.
    Jin X; Tian S; Li P
    Oncol Res; 2017 Jul; 25(6):939-946. PubMed ID: 27938492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin.
    Cai S; Bai Y; Wang H; Zhao Z; Ding X; Zhang H; Zhang X; Liu Y; Jia Y; Li Y; Chen S; Zhou H; Liu H; Yang C; Sun T
    J Exp Clin Cancer Res; 2020 Jul; 39(1):135. PubMed ID: 32669125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TR4 nuclear receptor enhances the cisplatin chemo-sensitivity via altering the ATF3 expression to better suppress HCC cell growth.
    Shen J; Lin H; Li G; Jin RA; Shi L; Chen M; Chang C; Cai X
    Oncotarget; 2016 May; 7(22):32088-99. PubMed ID: 27050071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of cyclophilin B in tumorigenesis and cisplatin resistance in hepatocellular carcinoma in humans.
    Kim Y; Jang M; Lim S; Won H; Yoon KS; Park JH; Kim HJ; Kim BH; Park WS; Ha J; Kim SS
    Hepatology; 2011 Nov; 54(5):1661-78. PubMed ID: 21748762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCAT1, a key prognostic predictor of hepatocellular carcinoma, promotes cell proliferation and induces chemoresistance to cisplatin.
    Zheng YH; Hu WJ; Chen BC; Grahn TH; Zhao YR; Bao HL; Zhu YF; Zhang QY
    Liver Int; 2016 Dec; 36(12):1836-1847. PubMed ID: 27246112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Astragaloside IV enhances cisplatin chemosensitivity in hepatocellular carcinoma by suppressing MRP2.
    Qu X; Gao H; Zhai J; Sun J; Tao L; Zhang Y; Song Y; Hu T
    Eur J Pharm Sci; 2020 May; 148():105325. PubMed ID: 32259679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vigilin is overexpressed in hepatocellular carcinoma and is required for HCC cell proliferation and tumor growth.
    Yang WL; Wei L; Huang WQ; Li R; Shen WY; Liu JY; Xu JM; Li B; Qin Y
    Oncol Rep; 2014 May; 31(5):2328-34. PubMed ID: 24676454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells.
    Hamaya S; Fujihara S; Iwama H; Fujita K; Shi T; Nakabayashi R; Mizuo T; Takuma K; Nakahara M; Oura K; Tadokoro T; Mimura S; Tani J; Morishita A; Kobara H; Ono M; Himoto T; Masaki T
    Anticancer Res; 2022 Mar; 42(3):1263-1275. PubMed ID: 35220216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
    Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
    Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the JNK signaling pathway increases sensitivity of hepatocellular carcinoma cells to cisplatin by down-regulating expression of P-glycoprotein.
    Liu XY; Liu SP; Jiang J; Zhang X; Zhang T
    Eur Rev Med Pharmacol Sci; 2016; 20(6):1098-108. PubMed ID: 27049263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of ZFX confers self-renewal and chemoresistance properties in hepatocellular carcinoma.
    Lai KP; Chen J; He M; Ching AK; Lau C; Lai PB; To KF; Wong N
    Int J Cancer; 2014 Oct; 135(8):1790-9. PubMed ID: 24585547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1.
    Qin J; Luo M; Qian H; Chen W
    Gene; 2014 Apr; 538(2):342-7. PubMed ID: 24447717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma.
    Lau CK; Yang ZF; Lam SP; Lam CT; Ngai P; Tam KH; Poon RT; Fan ST
    Cancer Biol Ther; 2007 Dec; 6(12):1900-7. PubMed ID: 18059167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-8 is related to poor chemotherapeutic response and tumourigenicity in hepatocellular carcinoma.
    Park SY; Han J; Kim JB; Yang MG; Kim YJ; Lim HJ; An SY; Kim JH
    Eur J Cancer; 2014 Jan; 50(2):341-50. PubMed ID: 24161763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis.
    Ding Z; Ericksen RE; Escande-Beillard N; Lee QY; Loh A; Denil S; Steckel M; Haegebarth A; Wai Ho TS; Chow P; Toh HC; Reversade B; Gruenewald S; Han W
    J Hepatol; 2020 Apr; 72(4):725-735. PubMed ID: 31726117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of SSR2 Enhances Hepatocellular Carcinoma Cisplatin Sensitivity via the Hippo Pathway.
    Ye R; Yin L; Ge Y; Zhu X; Xiao Y; Fang C; Liu Q; Zhang H; Li H; Xie B
    Front Biosci (Landmark Ed); 2024 Aug; 29(8):299. PubMed ID: 39206890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression.
    Lin XM; Hu L; Gu J; Wang RY; Li L; Tang J; Zhang BH; Yan XZ; Zhu YJ; Hu CL; Zhou WP; Li S; Liu JF; Gonzalez FJ; Wu MC; Wang HY; Chen L
    Gastroenterology; 2017 Apr; 152(5):1187-1202. PubMed ID: 28065789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.
    Tu C; Chen W; Wang S; Tan W; Guo J; Shao C; Wang W
    J Cell Mol Med; 2019 Nov; 23(11):7190-7199. PubMed ID: 30801960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.